Related Experiment Video
Updated: May 23, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
[The cardiologist and immunosuppressive therapy]
Pierre Ambrosi1, Pierre Lafforgue
1Hôpital de la Timone, service de cardiologie, 13385 Marseille, France. pierre.ambrosi@ap-hm.fr
Insights
Cardiologists must monitor patients on immunosuppressive therapy, especially those with heart failure. While TNF inhibitors are generally contraindicated in severe heart failure, they may be used cautiously in milder cases with close cardiac follow-up.
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Context:
- Cardiologists play a crucial role in managing patients undergoing immunosuppressive therapy.
- Specific considerations arise for patients with cardiac conditions, including heart failure and hypertension.
Purpose:
- To outline the cardiac monitoring requirements for patients on immunosuppressive therapy.
- To detail contraindications and precautions for using TNF inhibitors in heart failure.
- To guide the management of immunosuppression-induced arterial hypertension.
Summary:
- Tumor Necrosis Factor (TNF) inhibitors are contraindicated in NYHA Class III-IV heart failure, but etanercept may be an exception.
- For milder heart failure, TNF inhibitors can be used if no alternatives exist, requiring cardiac follow-up.
- Cyclosporine and tacrolimus are nephrotoxic and hypertensive; calcium-blockers and renin-angiotensin inhibitors are first-line for hypertension.
- Calcium-blockers can cause edema and increase calcineurin inhibitor levels; combined use with cyclosporine may lead to gingival hypertrophy and gynecomastia.
Impact:
- Provides essential guidance for cardiologists managing complex patient populations.
- Aims to optimize immunosuppressive therapy while minimizing cardiovascular risks.
- Contributes to safer and more effective patient care by highlighting drug interactions and side effects.
Abstract:
The monitoring of immunosuppressive therapy may involve the cardiologist in various settings. TNF inhibitors are contra-indicated in patients with NYHA III-IV cardiac failure. This contra-indication is not absolute for etanercept. In patients with milder forms of cardiac failure, TNF inhibitors can be prescribed in the absence of alternative therapy. A cardiac follow-up is necessary in this situation. Cyclosporine and tacrolimus are both nephrotoxic and hypertensive drugs. For the treatment of arterial hypertension induced by the immunosuppressive therapy, first-line recommended drugs are calcium-blockers and renin-angiotensin inhibitors. Other antihypertensive classes may also be used in these patients. Calcium-blockers may cause frequent oedema and plasma calcineurin-inhibitor concentration elevations. Moreover, cyclosporine+calcium-blocker association may induce gingival hypertrophy and gynecomastia.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Myocarditis III: Medical Management
Pericarditis III: Medical Management
Endocarditis III: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy